Latest Exelixis Stories

VANCOUVER, British Columbia, Aug. 10, 2012 /PRNewswire-Asia/ -- EarningForecast.com has issued consensus earnings forecast reports and Equity Research for the following companies: Sprint Nextel (NYSE:S), Cisco (NASDAQ:CSCO), News Corporation (NASDAQ:NWSA), Exelixis (NASDAQ:EXEL), Windstream (NASDAQ:WIN), and Intel (NASDAQ:INTC). (Logo: http://photos.prnewswire.com/prnh/20120809/HK54890LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...

VANCOUVER, British Columbia, Aug. 10, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Exelixis (NASDAQ:EXEL), Monster Beverage (NASDAQ:MNST), Delta Air Lines (NYSE:DAL), Robbins & Myers (NYSE:RBN), NRG Energy (NYSE:NRG), and CONSOL Energy (NYSE:CNX). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...

MENLO PARK, Calif., June 29, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. "With our lead antiviral program entering the clinic in the next year, we are committed to building a strong...

SAN FRANCISCO, Aug. 31 /PRNewswire/ -- Deloitte Recap recently presented the Allicense 2010 Breakthrough Alliance Award to pharmaceutical giant, Sanofi-aventis, and biotechnology firm, Exelixis, in recognition of their potential $1 billion alliance in which Exelixis gave Sanofi-aventis worldwide exclusive licenses for two early-stage cancer treatments and a stake in the development of PI3K inhibitor programs. In exchange, Sanofi-aventis provided Exelixis an upfront payment of $140 million...

BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ -- Change Change Change at Change at on a constant on a constant Q2 reported exchange reported exchange 2009 basis rates H1 2009 basis rates ------- --------- -------- ------- ------- -------...

Exelixis, a development-stage biotechnology company, has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to discover novel therapies targeted against the liver X receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through January 12, 2009....

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to discover novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through...

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. In the trial, XL765 is orally administered...

Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective. XL228 is a potent small molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R) and SRC, which are protein kinases known to promote cancer cell survival, proliferation, and migration. XL228 also inhibits BCR-ABL, a protein kinase...

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....